PURPOSE
Validation
Determine the utility of DCISionRT in reclassifying patients who met RTOG 9804 or ECOG-ACRIN E5194 ‘low-risk’ clinicopathologic criteria but remained at elevated invasive risk after BCS and benefited from RT.
STUDY
Complete biomarker and clinical data for 535 women meeting ‘good risk’ clinicopathologic criteria (negative margins vs wide margins) and 660 women meeting ECOG E5194 grade 1 or 2 criteria
SUMMARY
Outcomes in clinicopathological low-risk DCIS women after breast cancer surgery (BCS):
- DCISionRT Elevated Risk patients had substantial risk of 10-year invasive occurrence
- DS Elevated Risk patients (>3) had significant RT benefit (8-15% absolute difference)
- DS Low RIsk patients (≤3) had minimal RT benefit (1-2% absolute difference)